# Lisata Therapeutics Inc. (LSTA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $30M  
**Price:** $3.48 (-3.60%)

> Lisata Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other serious diseases. Its lead investigational product, certepetide, activates a novel uptake pathway via the CendR Platform technology, enabling co-administered or tethered anti-cancer drugs to selectively target and deeply penetrate solid tumors more effectively. This platform also targets immunosuppressive cells within the tumor microenvironment to enhance immune responses and immunotherapies. The company advances a broad clinical-stage pipeline, including trials such as ASCEND in metastatic pancreatic ductal adenocarcinoma, BOLSTER in cholangiocarcinoma, CENDIFOX in pancreatic, colon, and appendiceal cancers, iLSTA in locally advanced non-resectable pancreatic ductal adenocarcinoma, and studies in glioblastoma multiforme. Lisata Therapeutics Inc. maintains strategic partnerships, including a global non-exclusive license with Catalent for certepetide in antibody-drug conjugates and an alliance with GATC Health for AI-driven drug discovery. Founded in 1980 and headquartered in Basking Ridge, New Jersey, it operates in the oncology sector, addressing unmet needs in hard-to-treat cancers.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $170,000 | — | -$18M | -$17M | $-1.91 |
| 2024 | $1M | — | -$22M | -$20M | $-2.40 |
| 2023 | — | — | -$26M | -$21M | $-2.58 |
| 2022 | — | — | -$58M | -$54M | $-10.47 |
| 2016 | $35M | $4M | -$30M | -$33M | $-4.99 |
| 2015 | $22M | $2M | -$114M | — | — |
| 2014 | $18M | $2M | -$58M | -$55M | — |
| 2013 | $15M | $2M | -$37M | -$39M | — |
| 2012 | $14M | $2M | -$30M | -$54M | — |
| 2011 | $10M | $1M | -$34M | -$47M | — |
| 2010 | $70M | $20M | -$19M | -$23M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $18M | $3M | $15M | $16M | — |
| 2024 | $35M | $6M | $30M | $16M | — |
| 2023 | $55M | $7M | $48M | $23M | — |
| 2022 | $73M | $7M | $67M | $32M | — |
| 2016 | $54M | $30M | $5M | $7M | $3M |
| 2015 | $57M | $34M | $24M | $19M | $11M |
| 2014 | $126M | $68M | $59M | $19M | — |
| 2013 | $90M | $28M | $63M | $46M | $3M |
| 2012 | $54M | $21M | $33M | $14M | — |
| 2011 | $155M | $93M | $62M | $4M | — |
| 2010 | $143M | $94M | $49M | $16M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$16M | $28,000 | -$16M |
| 2024 | -$19M | — | -$19M |
| 2023 | -$20M | — | -$20M |
| 2022 | -$21M | $285,000 | -$21M |
| 2021 | -$22M | $60,000 | -$22M |
| 2020 | -$9M | $20,000 | -$9M |
| 2019 | -$19M | — | -$19M |
| 2018 | -$20M | $134,000 | -$20M |
| 2017 | -$21M | $135,000 | -$21M |
| 2016 | -$24M | $1M | -$25M |
| 2015 | -$39M | $3M | -$42M |
| 2014 | -$47M | $4M | -$51M |
| 2013 | -$27M | $3M | -$30M |
| 2012 | -$14M | $531,315 | -$14M |
| 2011 | -$21M | $574,857 | -$22M |

Source: [CompaniesByCap](https://companiesbycap.com/company/LSTA)